News | Biogen

September 1, 2021

Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Cambridge, MA.— Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference. The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section

August 2, 2021

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

List View Grid View

June 14, 2021

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

The Phase 3 STAR study did not meet primary or key secondary endpoints Choroideremia is a rare inherited retinal disease that results in progressive vision loss, ultimately leading to blindness CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.

June 10, 2021

Biogen Announces Investor Day on September 21, 2021

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies. The event will be webcast live on September 21, 2021 at 10:00 a.m. ET.

June 10, 2021

New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy

New data analysis suggests an investigational higher dose of SPINRAZA may lead to clinically meaningful improvements in motor function A NURTURE study analysis shows 92 percent of children who initiated SPINRAZA treatment as pre-symptomatic infants maintained the ability to swallow after

June 7, 2021

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

Programs now available to support patients and families with their treatment journey Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities Value-based agreements in progress with Cigna and other payers CAMBRIDGE, Mass.

June 7, 2021

FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease In clinical trials, ADUHELM reduced amyloid beta plaques by 59 to 71 percent at 18 months of treatment CAMBRIDGE, Mass. and TOKYO, June 07, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai ,

June 1, 2021

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritis CAMBRIDGE, Mass. and GUANGZHOU, China, June 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd.

May 25, 2021

Biogen Announces Webcast of Annual Meeting of Stockholders

Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor Relations section of the

May 21, 2021

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

Collaboration aims to develop a next-generation AAV production platform to help accelerate Biogen’s efforts to bring novel gene therapies to patients worldwide Ginkgo’s synthetic biology expertise may enable the expansion of therapeutic utility and overcome development challenges of viral vectors

May 20, 2021

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that its next generation manufacturing facility in Solothurn, Switzerland has received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products

May 14, 2021

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in several prespecified secondary endpoints, such as a clinically relevant measure of visual acuity Biogen will communicate next steps for the program after analyzing the complete data set Currently